CUE   $1.22  9.91% Market Closed After Close 1.1602 -4.90%

Cue Biopharma Inc
Last Events:

2023-08-09 Trend pattern changed from расширяющаяся формация to расходящийся треугольник.

2023-08-09 Signal in Stochastic changed from bullish reversal to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Trend Power changed from to medium strength.

2023-08-05 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-04 Trend pattern changed from расширяющийся канал to расширяющаяся формация.

2023-08-02 Signal in Stochastic changed from bearish weakening to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the oversold zone.

2023-08-02 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 5
Target Price Mean 4.00
Mean unverified/preliminary 4.00 / 4.00
Target Price Low / High 2.00 / 6.00
Median / STD DEV 4.00 / 2.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy ActivelyBuy
rsi ActivelyBuy ActivelyBuy ActivelyBuy
macd None None None
stoch None None None
ma20 Buy ActivelyBuy ActivelyBuy
ma50 None None None
ma100 ActivelyBuy ActivelyBuy ActivelyBuy
Candlestick PatternOct. 16, 2024 Long Legged - consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
ISIN US22978P1066
ceo Mr. Daniel R. Passeri J.D., M.Sc.
Website https://www.cuebiopharma.com
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.